Physician profile
Anna Worth
NPI 1023528726
$2,277.68
in general payments reported to CMS, 2019-2025
18 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $18.31 · 2021: $266 · 2022: $11.71 · 2023: $296 · 2024: $185 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $264.59 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $258.42 | 2023-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $232.62 | 2023-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $179.23 | 2022-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.60 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $123.95 | 2021 | |
| Gilead Sciences, INC. | $121.46 | 2019 | |
| Amgen INC. | $97.49 | 2025 | Evenity |
| Abbvie INC. | $72.69 | 2023-2025 | Ubrelvy |
| Pfizer INC. | $59.79 | 2025 | |
| Janssen Pharmaceuticals, INC | $57.77 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $46.40 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $27.11 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $27.09 | 2019-2023 | Korlym |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.60 | 2023 | Veozah |
| Verona Pharma, INC. | $23.42 | 2025 | Ohtuvayre |
| Medtronic, INC. | $17.17 | 2025 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Worth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.